NervGen Pharma (NGENF)
OTHER OTC:NGENF

NervGen Pharma (NGENF) Income Statement

42 Followers

NervGen Pharma Income Statement

Last quarter (Q ), NervGen Pharma's total revenue was C$―, a decrease of ― from the same quarter last year. In Q, NervGen Pharma's net income was C$-8.61M. See NervGen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----C$ 0.00C$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
C$ 17.78MC$ 17.78MC$ 23.03MC$ 12.81MC$ 11.20MC$ 8.24M
Operating Income
C$ -17.78MC$ -17.78MC$ -23.03MC$ -12.81MC$ -11.20MC$ -8.24M
Net Non Operating Interest Income Expense
C$ 550.07KC$ 550.07KC$ -313.20KC$ -29.42KC$ 18.85KC$ -1.37M
Other Income Expense
C$ 4.99MC$ 4.99MC$ -1.91MC$ 55.23KC$ -9.11KC$ -155.88K
Pretax Income
C$ -22.38MC$ -22.38MC$ -20.72MC$ -12.73MC$ -11.19MC$ -9.77M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -22.38MC$ -22.38MC$ -20.72MC$ -12.73MC$ -11.19MC$ -9.77M
Basic EPS
C$ -0.37C$ -0.38C$ -0.39C$ -0.32C$ -0.35C$ -0.38
Diluted EPS
C$ -0.37C$ -0.38C$ -0.39C$ -0.32C$ -0.35C$ -0.38
Basic Average Shares
C$ 237.16MC$ 59.29MC$ 52.65MC$ 39.29MC$ 32.11MC$ 25.90M
Diluted Average Shares
C$ 237.16MC$ 59.29MC$ 52.65MC$ 39.29MC$ 32.11MC$ 25.90M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 17.78MC$ 17.78MC$ 23.03MC$ -12.81MC$ 11.20MC$ 8.24M
Net Income From Continuing And Discontinued Operation
C$ -22.38MC$ -22.38MC$ -20.72MC$ -12.73MC$ -11.19MC$ -9.77M
Normalized Income
C$ -16.45MC$ -16.45MC$ -15.23MC$ -9.35MC$ -11.18MC$ -9.61M
Interest Expense
------
EBIT
C$ -22.38MC$ -22.38MC$ -20.21MC$ -12.73MC$ -11.20MC$ -8.24M
EBITDA
C$ -22.24MC$ -22.24MC$ -20.09MC$ -12.68MC$ -11.16MC$ -8.20M
Currency in CAD

NervGen Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis